News

A safety, tolerability, pharmacokinetics, and preliminary efficacy of avadomide in patients with advanced solid tumors, non-Hodgkin lymphomas, or multiple myeloma shows evidence of preliminary activity. Findings from the diffuse large B-cell cohort were published in Blood.

A new phase II trial showed higher pathological complete response rates in patients with HER2-positive breast cancer who took docetaxel, carboplatin, trastuzumab, and pertuzumab followed by trastuzumab emtansine, and pertuzumab, versus those who took only the former therapy.

“This combined genomic and epigenomic plasma-based ctDNA test continues to demonstrate high sensitivity and specificity which significant implications for its clinical utility of CRC detection,”

There is a significant unmet clinical need [for] treatment of CML globally. This Orphan Drug Designation from FDA marks a major milestone for HQP1351..."

In an interview with Targeted Oncology, Bruce L. Levine, PhD, discussed hot topics in the treatment landscape of melanoma, including the development of chimeric antigen receptor T and NK cells.

“Immune transcriptomic analyses of in silico and wet-lab cohorts of TP53-mutated AML suggest the presence of high T-cell infiltration and high expression of immune checkpoints and interferon-gamma signaling molecules compared with AML subgroups with other risk-defining molecular lesions."

In an interview with Targeted Oncology, Michael A. Davies, MD, PhD, discussed the current treatment landscape of melanoma and the recent advances that have provided a great level of optimism to what has been known to be a very challenging cancer setting.

"Atezolizumab combined with vemurafenib and cobimetinib showed a statistically significant and clinically meaningful in progression-free survival via investigator assessment when compared with placebo plus vemurafenib and cobimetinib."

In an interview with Targeted Oncology, Gregory L. Beatty, MD, PhD, discussed the science behind the development of metastases in pancreatic tumors, including how metastases differ in various sites in the body. He also reviewed the treatment options for this disease.

In an interview with Targeted Oncology, Sarat Chandarlapaty, MD, PhD, explained the mechanisms of resistance to CDK4/6 inhibitors. He also discussed new therapeutic strategies are being curated and implemented to overcome resistance in patients with ER-positive breast cancer.

Targeted Oncology reviews trending news online for the week of May 1, 2020, including recent updates from studies of COVID-19 and the latest oncology news.

The FDA has approved the use of daratumumab in combination with hyaluronidase-fihj (Darzalex Faspro) for the treatment of adult patients with newly diagnosed or relapsed/refractory multiple myeloma. The newly approved product allowed for subcutaneous dosing of daratumumab.

“The results that we’ve seen do suggest that there is some interaction between the two drugs, despite ongoing debate of whether this regimen after progression on a PD-1 inhibitor could be beneficial in clear cell renal cell carcinoma."

"The acceptance of our submission for CC-486 represents an important step towards a potential new maintenance treatment to address an urgent medical need for patients with AML and we look forward to working with the FDA during its review of CC-486."

The electrical impedance spectroscopy system , Nevisense 3.0, a third-generation of the SciBase Nevisense system, for the early detection of melanoma has been granted FDA approval.

Here’s a look back on the FDA happenings from the month of April 2020.

“We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing."

"As anticipated, the data continues to become more compelling with extended SGX301 treatment."

“The ATLANTIS trial reflects an exciting innovation in front-line precision cancer medicine for patients with advanced [urothelial cancer]."

"Over the last 12 years, an average of 9 practices per month have closed, been acquired by a hospital, or merged. These are troubling trends and dangerous for patients battling cancer...”

In an interview with Targeted Oncology, Elizabeth M. Swisher, MD, discussed data for PARP inhibitor maintenance therapy in patients with ovarian cancer, including the VELIA study of veliparib and the ARIEL3 trial of rucaparib.

In an interview with Targeted Oncology, Luca dos Santos, MD, MsC, discussed the combination of irinotecan plus cisplatin in comparison to gemcitabine and cisplatin as treatment of patients with metastatic or unresectable biliary tract cancer.

The FDA's Fast Track designation for second-line eryaspase as treatment of patients with metastatic pancreatic cancer underscores the need for new treatment options in this patient population.

A manageable safety profile was demonstrated with the combination of atezolizumab plus an anti-CD19 chimeric antigen receptor T-Cell therapy in patients with refractory diffuse large B-cell lymphoma in the ZUMA-6 trial.

A new dosage for pembrolizumab of 400 mg administered every 6 weeks across all adult indications has been approved by the FDA, whether the PD-1 inhibitor is used as monotherapy or in a combination regimen.

"The confirmation of the initial safety profile of NOX-A12 in combination with radiotherapy in all patients of the first cohort is very encouraging."

Deep and durable responses were observed in 97 patients with advanced non–small cell lung cancer harboring a MET exon 14 mutation with treatment of capmatinib, according to GEOMETRY mono-1 study, presented at the 2020 American Association for Cancer Research Annual Meeting.

Interim findings of the ongoing phase II ZENITH20 trial demonstrated that poziotinib induced a 68.7% disease control rate when used as treatment of patients with pretreated non–small cell lung cancer harboring an EGFR exon 20 insertion.

Few options exist for patients with relapsed or refractory large B-cell lymphomas who have already undergone 2 rounds of systemic therapy. New research shows axicabtagene ciloleucel might be a strong option, but community oncologists must play a role in patient identification and post-treatment follow-up.

"Because pacritinib inhibits JAK2, IRAK-1, and CSF1R, there is real potential for pacritinib to prevent patients from developing an inflammatory response to the coronavirus infection and subsequent pulmonary failure, therefore reducing the need for a ventilator."